Metabolic health
Blood tests during GLP-1 care: what each result can tell you
Blood tests can help assess diabetes, cardiometabolic risk, and problems arising during treatment. A useful plan asks what decision a test will inform rather than ordering every available marker.
HbA1c and short-term glucose
HbA1c estimates average blood glucose over roughly 3 months, with recent weeks contributing more strongly. NIDDK describes values below 5.7% as the usual normal range, 5.7–6.4% as the prediabetes range, and 6.5% or higher as a diabetes threshold requiring appropriate clinical confirmation.
Anemia, changes in red blood cells, hemoglobin variants, and some other conditions can affect interpretation. A fasting glucose, home glucose reading, and HbA1c measure different things. A clinician should reconcile unexpected differences rather than choosing whichever number looks reassuring.
Sources: NIDDK: the A1C test and diabetes
Kidney measures and hydration
Kidney function can matter because vomiting and diarrhea may cause dehydration and kidney injury. Clinicians may review creatinine, estimated filtration, electrolytes, or other tests when symptoms and medical history justify them.
Ozempic's kidney-risk reduction indication applies to adults with type 2 diabetes and chronic kidney disease. It does not mean that everyone taking any GLP-1 receives the same protection or that dehydration becomes harmless.
Sources: Ozempic prescribing information · Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information
Lipids and other targeted testing
Lipid measures can inform cardiovascular-risk management, while other tests may assess a separate condition or symptom. Changes should be interpreted in the context of diet, weight, other medicines, and existing risk factors rather than attributed automatically to one prescription.
Ask why a test is being ordered, what a concerning result would change, and who reviews it. A thyroid blood test is not a universal clearance test for the MTC/MEN 2 contraindication, and routine tumor-marker screening should not be promised as a proven GLP-1 safety strategy.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information
A useful monitoring conversation
Review baseline diagnoses, diabetes treatment, hypoglycemia risk, pregnancy plans, symptoms, and follow-up access. Ask which blood tests and home measurements are appropriate and when to repeat them. A CGM is a separate decision; it is not required for every weight-management patient.
Keep test results and medicine changes available to the prescriber. Persistent severe symptoms should receive care when they occur rather than wait for a scheduled lab draw.
Sources: NIDDK: the A1C test and diabetes · Wegovy prescribing information, including tablets and Wegovy HD · Mounjaro prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.